Shots:
CB Biotechnology has entered into a definitive agreement to acquire Theratechnologies, delisting it from public markets
As per the deal, Theratechnologies’ shareholders will receive $3.01/share in cash & a non-tradeable CVR of $1.19/share tied to company milestones, with total CVR payments limited to $65M, making it an aggregate of $254M, assuming full CVR payout;…
